What Should a Breast Fibrosis Biopsy Report Include?

When a breast biopsy returns a diagnosis of “stromal fibrosis” or “fibrocystic change,” the relief of seeing the word “benign” can sometimes overshadow an equally important question: Did the biopsy successfully sample the area of concern seen on your imaging? A pathology report describing benign fibrosis is only reassuring if that diagnosis adequately explains the abnormality targeted during the biopsy ^[1]. To ensure your diagnosis is accurate, your care team must compare your tissue results with your imaging results.

The Three Documents You May Need

Patients often expect the pathology report to contain every detail about the biopsy. In reality, the full picture comes from combining information across three different medical records:

1. The Radiology Report: Details the original abnormal finding—such as a mass, “architectural distortion” (where breast tissue looks pulled or arranged abnormally on a mammogram), or “non-mass enhancement” on an MRI. It notes the location (often described like numbers on a clock face) and the suspicion level, usually graded on the BI-RADS scale ^[2][3].
2. The Biopsy Procedure Note (or Post-Biopsy Mammogram): Confirms exactly what area was targeted, whether targeted calcifications were successfully collected into the needle, and where a tiny metallic marker clip was placed to mark the biopsied spot.
3. The Pathology Report: Provides the microscopic diagnosis of the tissue that was removed ^[4].

Key Details in Your Pathology Report

When reviewing the pathology report itself, look for the following essential details:

1. The Microscopic Diagnosis

The report should clearly describe the benign findings. Stromal fibrosis (a benign overgrowth of fibrous connective tissue) is a specific diagnosis ^[3]. The report may also list other benign fibrocystic changes like cysts or apocrine metaplasia (benign changes to duct cells). It might also identify separate benign patterns, such as sclerosing adenosis (enlarged breast lobules with scar-like tissue) ^[5].

2. Absence of Cancer and High-Risk Features

The report will indicate that no cancer was found. While some reports explicitly list the absence of ductal carcinoma in situ (DCIS) or invasive carcinoma ^[6], many simply use a reassuring summary phrase like “negative for malignancy.” The pathologist should also evaluate for atypia (abnormal cells associated with a higher future breast cancer risk) ^[7][8]. If atypia or high-risk lesions are found, they require different management than simple fibrosis.

3. Specimen Limitations and Calcifications

If the tissue sample was too small, highly fragmented, or damaged (crush artifact) to interpret clearly, the pathologist will note this limitation ^[9]. If you had a biopsy because of suspicious calcium deposits, either the pathology report or the specimen X-ray must confirm that calcifications were actually captured in the sample ^[10][11].

The Final Step: Radiologic-Pathologic Concordance

The most critical step happens after the pathology report is finalized. Your breast radiologist and care team will compare the microscopic pathology results against the original imaging to determine radiologic-pathologic concordance ^[12].

Because stromal fibrosis can mimic cancer on imaging, finding benign fibrosis in the tissue is only reassuring if it is a logical explanation for what the imaging showed ^[2][1].

When Results Are Concordant

If the breast radiologist determines the fibrosis adequately explains the imaging finding, the results are considered concordant. In these cases, simple fibrosis usually does not require treatment or surgical removal. Your doctor will typically recommend returning to routine screening or having a short-interval follow-up imaging scan (often in 6 months) ^[13].

When Results Are Discordant

If the original imaging was highly suspicious (such as a BI-RADS 4 or 5 assessment) but the biopsy only found non-specific benign tissue like fibrosis, the radiologist may judge the results as discordant ^[14]. This means the benign tissue doesn’t explain the abnormal imaging, raising the possibility that the biopsy needle missed the true target (a false-negative result) ^[15].

A discordant benign report is not a stopping point. To resolve the discrepancy and reduce the risk of a missed lesion, your care team will likely recommend further evaluation. This may involve a repeat needle biopsy (such as a vacuum-assisted biopsy) or a surgical excision (a minor operation to remove the area for complete testing) ^[2][16].